Schneider LS, Kennedy RE, Cutter GR, . Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010 Sep;6(5):367-77. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Barcelona: 10th AD/PD Conference Hosts a Shaken, Restive Field
  2. Barcelona: Straight Talk From a Regulator on Trials in Parkinson’s
  3. Clinical Trials: Task Force Supports Earlier Intervention

Webinars

  1. Computational Modeling—Will it Rescue AD Clinical Trials?